Category Archives: Statins
Lipoprotein Kinetics in Male Hemodialysis Patients Treated with Atorvastatin.
Hemodialysis.com eInterview with Prof. Hans Dieplinger PhD
Division of Genetic Epidemiology
Department of Medical Genetics, Clinical and Molecular Pharmacology
Innsbruck Medical University
Schöpfstrasse 41
A-6020 Innsbruck Austria
email hans.dieplinger@i-med.ac.at
Written Interview conducted with author by Editor Marie Benz, MD
Hemodialysis.com: What are the main findings of the study?
Dr. Dieplinger: Our study was based on previous investigations from our group on the kinetics of atherogenic lipoproteins in hemodialysis patients. These former studies revealed a metabolic disorder of diminished synthesis AND degradation of apoB-containing lipoproteins resulting in prolonged residence times in circulation of these lipoproteins despite of their concentrations in normal ranges. The aim of our recent study was therefore to test whether HMG-CoA-reductase inhibitors (statins) which are known to normalize impaired degradation of apoB-containing lipoproteins in hypercholesterolemic patients exert similar beneficial effects also in CKD patients treated with hemodialysis. The main findings in a small group of male hemodialysis patients were significant reductions of total and LDL cholesterol as well as improved kinetics (including residence times) of atherogenic lipoproteins.
Marie Benz, MD on Google+Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy – a meta-analysis of 11 randomized controlled trials involving 21,295 participants
Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy – a meta-analysis of 11 randomized controlled trials involving 21,295 participants
Prof. Maciej Banach, MD, FNLA, FAHA, FESC, FASA, FRSPH
President, Polish Lipid Association
http://www.polishlipidassociation.com
Editor-in-chief, Archives of Medical Science
http://www.ArchivesofMedicalScience.com
Head, Department of Hypertension
Chair of Nephrology and Hypertension
Medical University of Lodz, Poland
E-mail: maciej.banach@umed.lodz.pl
Hemodialysis.com: What are the main findings of the study?
Dr. Banach: The use of statins in subjects with non-dialysis-dependent chronic kidney disease (CKD) resulted in a marked (statistically significant) reduction in death from all causes, cardiac causes, cardiovascular events and stroke. The use of statins in dialysis-dependent CKD patients resulted in a non‑significant effect on death from all causes and stroke, but had the effect of reducing death from cardiac causes and cardiovascular events (however the last two data were obtained on the very limited studies).
